Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma

Modern Pathology

Volumn 22, Issue 3, 2009, Pages 345-350

  Jarboe, Elke A ^a   Pizer, Ellen S ^b   Miron, Alexander ^c   Monte, Nick ^a   Mutter, George L ^a   Crum, Christopher P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b CellNetix Pathology   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

endometrial neoplasia; Intraepithelial carcinoma; p53; Serous carcinoma

Indexed keywords

GENOMIC DNA; PROTEIN P53;

ARTICLE; CANCER INVASION; CLINICAL FEATURE; CONTROLLED STUDY; DNA DAMAGE; ENDOMETRIUM CARCINOMA; ENDOMETRIUM POLYP; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA IN SITU;

AGED; AGED, 80 AND OVER; CELL TRANSFORMATION, NEOPLASTIC; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYPS; PRECANCEROUS CONDITIONS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 61349126094     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.197     Document Type: Article

References (21)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Hendrickson M, Ross J, Eifel P, et al. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982;6:93-108.
3. Chambers JT, Merino M, Kohorn EI, et al. Uterine papillary serous carcinoma. Obstet Gynecol 1987;69:109-113.
4. Ambros RA, Sherman ME, Zahn CM, et al. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 1995;26:1260-1267.
5. Jia L, Liu Y, Yi X, et al. Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin Cancer Res 2008;14:2263-2269.
6. Fadare O, Zheng W. Endometrial glandular dysplasia (EmGD): morphologically and biologically distinctive putative precursor lesions of type II endometrial cancers. Diagn Pathol 2008;8:3:6.
7. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995;26:1268-1274.
8. Lomo L, Nucci MR, Lee KR, et al. Histologic and immunohistochemical decision-making in endometrial adenocarcinoma. Mod Pathol 2008;21:937-942.
9. Cass I, Holschneider C, Datta N, et al. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? Obstet Gynecol 2005;106:1327-1334.
10. Beiner ME, Finch A, Rosen B, , et al., Hereditary Ovarian Cancer Clinical Study Group. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol 2007;104:7-10.
11. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006;3:230-236.
12. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007;25:3985-3990.
13. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007;31:161-169.
14. Carlson J, Miron A, Jarboe E, et al. Serous tubal intraepithelial carcinoma (STIC): Its potential role in primary peritoneal serous cancer (PPSC) and serous cancer prevention. J Clin Oncol 2008;26:4160-4165.
15. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007;211:26-35. Erratum in: J Pathol. 2007;213:116.
16. Jarboe E, Folkins A, Nucci MR, et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol 2008;27:1-9.
17. Folkins AK, Jarboe EA, Saleemuddin A, et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 2008;109:168-173.
18. Saleemuddin A, Folkins AK, Garrett L, et al. Risk factors for a serous cancer precursor ('p53 signature') in women with inherited BRCA mutations. Gynecol Oncol 2008;111:226-232.
19. Thiriet C, Hayes JJ. Chromatin in need of a fix: phosphorylation of H2AX connects chromatin to DNA repair. Mol Cell 2005;18:617-622.
20. Williams C, Ponten F, Moberg C, et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am J Pathol 1999;155:1467-1471.
21. Liang SX, Chambers SK, Cheng L, et al. Endometrial glandular dysplasia: a putative precursor lesion of uterine papillary serous carcinoma. Part II: molecular features. Int J Surg Pathol 2004;12:319-331.